Back to Peptides

Sermorelin

Growth Factors & Muscle Building

Sermorelin is a synthetic GHRH analog that stimulates the pituitary to release natural growth hormone, offering a safer and more physiologic alternative to direct GH therapy. Commonly used in adults with GH deficiency, it supports sleep, fat metabolism, recovery, and muscle tone.

Reconstitute
3 mL BAC + 1mg vial
3 mcg/unit
Daily Range
1–2 mcg Subcutaneous (SQ)
Daily
Standard Dose
1.5 mcg
Cycle
4–8 weeks
then reassess
SermorelinGHRH analoggrowth hormoneGH stimulationpituitary function

Dosing & Reconstitution Guide

In research, Sermorelin has been administered at doses ranging from 100–500 μg per day via subcutaneous injection in animal models and clinical test settings. These doses are investigational and not approved for general use.

Standard / Gradual Approach

standard
PhaseDoseVolume
Week 1100mcg
Week 2100mcg
Week 3150mcg
Week 4200mcg

Protocol Summary

Subcutaneous (SQ): Daily · Dose range 12 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Inject daily at night to mimic natural GH rhythms. Suggested cycle is 8–12 weeks on followed by a 4-week break.

🧪 Quick Start

BAC Water
3 mL

Potential Benefits & Use Cases

Sermorelin is a research-use-only compound. It is not approved for human or veterinary use outside of regulated clinical testing. All content is for scientific and educational purposes only.
Stimulates endogenous pulsatile GH release, supporting physiologic IGF-1 elevation (human trial)
Significant improvements in height velocity in pediatric GH deficiency over 6–12 months (FDA-approved)
May support favorable body composition, energy, and recovery in adults (limited human data — off-label)
Preserves physiologic feedback, reducing risk of supraphysiologic GH levels compared to exogenous GH (human trial)
Clinical data Strong preclinical Limited data

Mechanism of Action

Stimulates release of growth hormone from the anterior pituitary
Mimics the action of endogenous growth hormone-releasing hormone (GHRH)

Lifestyle & Optimization

timing

Prioritize evening injections to align with natural GH secretion patterns.

diet

Maintain adequate carbohydrate intake to support GH response. Adequate protein.

exercise

Resistance training 4–5 times weekly.

sleep

Sleep 8+ hours nightly for GH release optimization.

Peptide Research & Preclinical Studies

Side Effects & Safety

Common Side Effects

Injection-site reactions (~17% incidence in trials)
~6.5% developed subclinical hypothyroidism; untreated hypothyroidism blunts GH response

Contraindications & Warnings

Rare systemic effects (<1%): headache, flushing, dizziness, hives

🧮 Dose Calculator

Concentration
3.3
mcg/unit
Draw Volume
150
units (1.500 mL)
For a 500 mcg dose, draw 150 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High systemic absorption with effective GH release
Oral Administration
Very poor bioavailability; rapidly degraded by GI enzymes
Half-Life
Approximately 12 minutes
Degradation
Primarily metabolized by hepatic and renal peptidases
Tissue Specificity
Targets pituitary GHRH receptors to trigger GH secretion
⚗️

Peptide Details

Molecular Weight
3357.882
Formula
C149H246N44O42S
Sequence
HAGGGYTDAIFNSYRK-VNRRG
⚖️

Legal Status & Regulatory

RegionStatus
FDAApproved
EUApproved
AustraliaApproved
CanadaApproved

Storage Instructions

Lyophilized (Powder)
Store lyophilized powder at 2-8°C
Reconstituted (Mixed)
After reconstitution, maintain at 2-8°C and use within 30 days. Sermorelin is relatively stable compared to other peptides.